0001104659-24-032002.txt : 20240307
0001104659-24-032002.hdr.sgml : 20240307
20240307190235
ACCESSION NUMBER: 0001104659-24-032002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240305
FILED AS OF DATE: 20240307
DATE AS OF CHANGE: 20240307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ronsheim Matthew
CENTRAL INDEX KEY: 0001824386
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30319
FILM NUMBER: 24731911
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Innoviva, Inc.
CENTRAL INDEX KEY: 0001080014
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943265960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1350 OLD BAYSHORE HIGHWAY
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: 6502389600
MAIL ADDRESS:
STREET 1: 1350 OLD BAYSHORE HIGHWAY
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
FORMER COMPANY:
FORMER CONFORMED NAME: THERAVANCE INC
DATE OF NAME CHANGE: 20020207
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MEDICINE INC
DATE OF NAME CHANGE: 20000302
4
1
tm248180-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-03-05
0
0001080014
Innoviva, Inc.
INVA
0001824386
Ronsheim Matthew
35 GATEHOUSE DRIVE
WALTHAM
MA
02451
0
1
0
0
See Remarks
0
Common Stock
2024-03-05
4
A
0
12768
14.88
A
40778
D
Non-statutory Stock Option
14.88
2024-03-05
4
A
0
27338
0
A
2025-02-20
2034-03-05
Common Stock
27338
120438
D
The Reporting Person was granted a one time-based restricted stock unit ("RSU"). Twenty-five percent of the shares subject to the RSU shall vest on February 20, 2025, 6.25% on May 20, 2025, and an additional 6.25% on the final day of each 3-month period thereafter, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The grant was approved by the Compensation Committee of the Board of Directors of the Company.
25% of the options will vest on February 20, 2025 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Dr. Ronsheim's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Dr. Ronsheim experiences a termination of employment by the Innoviva, Inc. without "cause" or by Dr. Ronsheim for "good reason" (each as defined in Dr. Ronsheim's employment agreement) within 24 months following a "change in control," subject to an effective release of claims.
Dr. Ronsheim is President of Innoviva Specialty Therapeutics, Inc. which is a wholly owned subsidiary of Innoviva Specialty Therapeutics Holdings, LLC, which is a wholly owned subsidiary of Innoviva, Inc.
/s/ Matthew Ronsheim
2024-03-07